

Georgia Department of Community Health

DRUG UTILIZATION REVIEW BOARD MEETING

Department of Community Health 2 Peachtree Street – 5th Floor Board Room Atlanta, Georgia 30303

May 4, 2017







DRUG UTILIZATION REVIEW BOARD MEETING

AGENDA 2 Peachtree Street - 5th Floor DCH Board Room Atlanta, Georgia 30303 Thursday, May 4, 2017 11:00 a.m. to 2:00 p.m.

CALL TO ORDER	Deborah Fincher, RPh, Chair
MINUTES FROM PREVIOUS MEETING	Chair
EXTERNAL COMMENTS SESSION	Chair
CLINICAL REVIEWS	Afzal Mistry, PharmD, NorthStar Chad Nicholson, PharmD, NorthStar Emily Baker, PharmD, BCPS, NorthStar
 New Drugs Spinraza 	Emily Baker, 1 narmD, DCI 5, NormSiar
Supplemental Rebate Classes	
ADJOURNMENT OF OPEN SESSION	Chair
EXECUTIVE SESSION	Steve Liles, PharmD, Senior Director, Change Healthcare
R ECONVENING OF O PEN SESSION	Chair
BOARD'S RECOMMENDATIONS AND VOTES	Chair
Future Agenda Items	Chair
ADJOURNMENT OF MEETING	Chair





Department of Community Health Drug Utilization Review Board (DURB) MINUTES Tuesday, February 7, 2017

Department of Community Health Drug Utilization Review Board (DURB) MINUTES Tuesday, February 7, 2017

MEMBERS PRESENT

MEMBERS ABSENT

Deborah Fincher, M.S., R.Ph., Chair Burton L. Lesnick, M.D., FAAP, Vice-Chair Mia Avery, Pharm.D. Gurinder J.S. Doad, M.D. Rod M. Duraski, M.D., FACP, MBA M. Celeste Fowler, Pharm.D. Glenda Wrenn Gordon, M.D. Yolanda P. Graham, M.D. Mary S. Harris, Ph.D. Robyn Lorys, Pharm.D. Osgood (Drew) A. Miller, R.Ph. Brent L. Rollins, R.Ph., Ph.D. Danny A. Toth, R.Ph. Douglas Collins, M.D. J. Russell May, Pharm.D.

<u>Staff</u>

Peter D'Alba, R.Ph., Pharmacy Director, Pharmacy Services Turkesia Robertson-Jones, Pharm.D., Pharmacy Operations Manager, Pharmacy Services Gilletta Gray, R.Ph., Clinical Manager, Pharmacy Services Lori Garner, MHS, MBA, R.Ph., Pharmacist, Pharmacy Services Cindy Nee, Pharm.D. Candidate (Mercer) Karla Forbes, Pharm.D., Program Integrity

NorthStar HealthCare Consulting

Emily Baker, Pharm.D., BCPS, MHA, MBA, President Afzal "Fez" Mistry, Pharm.D., Clinical Pharmacist Chad Nicholson, Pharm.D., Clinical Pharmacist Nekia Austin, Pharm.D., Esq., CFE, Program Compliance Director

OptumRx

Mark Hall, MBA, PMP, Assoc. Director, Government Markets, Relations & Reform Talmahjia "Tami" Sweat, Pharm.D., Director, Clinical Management

Change Healthcare

Doug Martin, Pharm.D., Pharmacy Project Manager

Department of Community Health Drug Utilization Review Board (DURB) MINUTES Tuesday, February 7, 2017 Call to Order

Call to Order

The Drug Utilization Review Board (DURB/DUR Board/Board) held its first meeting for the calendar year on February 7, 2017. The Chair, Deborah Fincher, M.S., R.Ph., called the meeting to order at 9:33am.

Comments from the Department

There were no comments from the Department.

Minutes from the Previous Meeting

Chair Fincher asked for corrections or changes to the minutes from the December 13, 2016 meeting. A motion was made (Burton L. Lesnick, M.D.), seconded (Osgood (Drew) A. Miller, R.Ph.), and carried to approve the minutes as written.

External Comments Session

External comments were presented to the Board from the following:

- Kathryn Pease son has Muscular Dystrophy; spoke about coverage for Exondys 51 and their experience with it.
- Gretchen Agans son has Muscular Dystrophy; spoke about experience with trial drug and coverage for Exondys 51 and future similar drugs.

Disclosure forms were completed by Kathryn Pease and Gretchen Agans and were reviewed by the Department.

New Drug Reviews

Clinical information for the following new drugs, in the market six months or more, was presented for discussion and recommendations. The complete detailed drug summary is in the New Drugs for Review section of the DUR Board binder.

Therapeutic Class	Drugs	Presenter
Duchenne Muscular Dystrophy	Exondys 51	Chad Nicholson, Pharm.D.
von Willebrand Factor Products	Vonvendi	Chad Nicholson, Pharm.D.
Ophthalmic Immunomodulators	Xiidra	Afzal Mistry, Pharm.D.
Gout Agents	Zurampic	Afzal Mistry, Pharm.D.

The Board discussed the drug information, provided comments, and raised questions on the following:

- Exondys 51
 - Guidelines to initiate therapy when patients plateau or decline in muscular function; indefinite therapy
 - Costs pricing structure is \$700,000-\$750,000/year
 - Increase in dystrophin but clinical outcomes were worse; two outliers but was an increase in 6 min. walk time; not a large enough patient sample size to say those functional endpoints are favorable but this is ongoing in Phase 3 trial

Tuesday, February 7, 2017

- Study 2 (follow-up of Study 1)- twins that lost ambulatory function were included in the Study 2 group
- Less drastic decline in motor function from data presented
- Phase 3 trials will have more patients
- Population in Georgia that could be treated approximately 60 patients (35-40 potential FFS patients)
- Other functional variables being looked at in the Phase 3 group: percentage of dystrophin positive fibers; ability to rise independently from floor; North Star Ambulatory Assessment; loss of ambulation and cardiac and pulmonary function
- Xiidra
 - Quite a few patients followed for a year for adverse events
 - In comparing Restasis/Xiidra end result is the same, both decrease inflammation in Dry Eye Disease
 - No current feedback from physicians using it
- Zurampic
 - o 3% or less experienced cardiovascular events
 - Used in combination with a Xanthine Oxidase Inhibitor (typically after XOI w/Probenecid)
 - no specific points in subpopulation

DCH Decisions

DCH Decisions from the December 2016 DUR Board meeting were provided in the DCH Decision section of the DUR Board binder.

Upcoming Meetings

The following upcoming meetings were published in the DURB binder:

Drug Utilization Review Board
 2 Peachtree Street NW
 5th Floor Board Room
 Atlanta, Georgia 30303

Thursday, May 4, 2017 Thursday, August 3, 2017 Tuesday, November 7, 2017

 Manufacturers' Forum NorthStar Healthcare Consulting 1121 Alderman Drive Suite 112 Alpharetta, Georgia 30005

> Thursday, March 30, 2017 Thursday, June 29, 2017 Tuesday, October 3, 2017

Department of Community Health Drug Utilization Review Board (DURB) MINUTES Tuesday, February 7, 2017 Disclosure Forms

Disclosure Forms

Disclosure forms were received and reviewed by the Department for completeness for all Board members attending the meeting.

Adjournment of Open Session

The DUR Board voted to close the open meeting pursuant to the Open Meeting Act of Georgia Section 50-14-1 – 50-14-6 and pursuant to Federal Law Section 1396R-8B3D. The individuals recorded in attendance with the Board members were from the Department of Community Health, Change Healthcare, NorthStar HealthCare Consulting, and OptumRx. Pharmacy student, Cindy Nee, attended the closed session with Board members. A motion was made by Robyn Lorys, Pharm.D., and seconded by Danny Toth, R.Ph.., to adjourn the open session and approve the closed session. There was a unanimous vote approving the closed session. The Chairman, Deborah Fincher, M.S., R.Ph., adjourned the open session at approximately 10:49am, at which time members took a break then reconvened for the executive (closed) session.

Executive Session

The Executive Session was held from 11:07am to 12:03pm.

Reconvening of Open Session

The DUR Board reconvened for the open session at 12:07pm.

Board's Recommendations to the Department

After all clinical and financial evaluations and discussions, the DUR Board voted and presented the Department with the following recommendations for changes to the Preferred Drug List (PDL). All motions and votes are noted in Attachment A.

New Drugs Classes

Duchenne Muscular Dystrophy

The DUR Board provided *No Recommendation at this time* for *Exondys 51* (*Intravenous*) *Injection*.

von Willebrand Factor Products

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Vonvendi (Intravenous) Injection*.

Ophthalmic Immunomodulators

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Xiidra (Ophthalmic) Solution*.

Gout Agents

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Zurampic (Oral) Tablet*.

Department of Community Health Drug Utilization Review Board (DURB) MINUTES Tuesday, February 7, 2017

Future Agenda Items

The following future agenda items were noted:

- Epipen
- Onfi-utilization

Conclusion

At the conclusion of the reconvened open session and no other business for discussion, there was a unanimous decision to adjourn the meeting. Chair Fincher adjourned the meeting at 12:11pm.

THESE MINUTES ARE HEREBY APPROVED AND ADOPTED, THIS THE _____ DAY OF _____, 2017.

Deborah Fincher, M.S., R.Ph., Chair

Drug Utilization Review Board

Motions - Votes - New Drugs

FEBRUARY 7, 2017

New Drug	Drug	PDL Status	Motion - Recommendations	Additional	Comments
Duchenne Muscular Dystrophy	Exondys 51 (Intravenous) Injection	Under Review	None	No recommendations at this time.	
Board Members - Present	Motion	Seconded		VOTES	
(Strike out, when absent)	Maker (V)	Ву (√)	YES (V)	NO (√)	ABSTAIN (√)
1 Avery, Mia, Pharm.D.			√		1
2 Doad, Gurinder J.S., M.D			√		
3 Duraski, Rod, M.D.			√		
4 Fincher, Deborah W., M.S., R.Ph Chair					
5 Fowler, M. Celeste, Pharm.D.			√		
6 Gordon, Glenda Wrenn			\checkmark		
7 Graham, Yolanda, M.D.			\checkmark		
8 Harris, Mary, Ph.D.			\checkmark		
₉ Lesnick, Burton, M.D Vice	\checkmark		\checkmark		
10 Lorys, Robyn Pharm.D.		\checkmark	\checkmark		
11 Miller, Osgood (Drew) A. R.Ph.			\checkmark		
12 Rollins, Brent L., R.Ph., Ph.D.			\checkmark		
13 Toth, Danny, R.Ph.			\checkmark		
		TOTAL	12	0	0
Board Members - Absent	-				
1 Collins, Douglas, M.D.					
2 May, J. Russell (Rusty)	-				
New Drug	Drug	PDL Status	Motion - Recommendations	Additional	Comments
von Willebrand Factor Products	Vonvendi (Intravenous) Injection.	NPPA	NPPA		
Board Members - Present	Motion	Seconded		VOTES	1
(Strike out, when absent)	Maker (√)	Ву (√)	YES (√)	NO (V)	ABSTAIN (√)
1 Avery, Mia, Pharm.D.			\checkmark		

Drug Utilization Review Board

Motions - Votes - New Drugs

FEBRUARY 7, 2017

2 Doad, Gurinder J.S., M.D			\checkmark		
3 Duraski, Rod, M.D.			\checkmark		
4 Fincher, Deborah W., M.S., R.Ph Chair					
5 Fowler, M. Celeste, Pharm.D.			\checkmark		
6 Gordon, Glenda Wrenn			\checkmark		
7 Graham, Yolanda, M.D.		\checkmark	\checkmark		
8 Harris, Mary, Ph.D.			\checkmark		
9 Lesnick, Burton, M.D Vice			\checkmark		
10 Lorys, Robyn Pharm.D.			\checkmark		
11 Miller, Osgood (Drew) A. R.Ph.	\checkmark		\checkmark		
12 Rollins, Brent L., R.Ph., Ph.D.			\checkmark		
13 Toth, Danny, R.Ph.			\checkmark		
		ТОТА	40	0	0
		TOTAL	12	U	U
Board Members - Absent		TOTAL	12	U	V
Board Members - Absent 1 Collins, Douglas, M.D.	_	TOTAL	12	U	, v
	-	TOTAL	12	U	
1 Collins, Douglas, M.D.	-		12		
1 Collins, Douglas, M.D.	Drug	PDL Status	Motion - Recommendations		Comments
1 Collins, Douglas, M.D. 2 May, J. Russell (Rusty)	Drug Xiidra (Ophthalmic) Solution.		Motion -		
1 Collins, Douglas, M.D. 2 May, J. Russell (Rusty) New Drug		PDL Status	Motion - Recommendations		Comments
1 Collins, Douglas, M.D. 2 May, J. Russell (Rusty) New Drug Ophthalmic Immunomodulators	Xiidra (Ophthalmic) Solution.	PDL Status Under Review	Motion - Recommendations	Additional	
1 Collins, Douglas, M.D. 2 May, J. Russell (Rusty) New Drug Ophthalmic Immunomodulators Board Members - Present	Xiidra (Ophthalmic) Solution. Motion	PDL Status Under Review Seconded	Motion - Recommendations NPPA	Additional	Comments
1 Collins, Douglas, M.D. 2 May, J. Russell (Rusty) New Drug Ophthalmic Immunomodulators Board Members - Present (Strike out, when absent)	Xiidra (Ophthalmic) Solution. Motion	PDL Status Under Review Seconded	Motion - Recommendations NPPA YES (V)	Additional	Comments
1 Collins, Douglas, M.D. 2 May, J. Russell (Rusty) New Drug Ophthalmic Immunomodulators Board Members - Present (Strike out, when absent) 1 Avery, Mia, Pharm.D.	Xiidra (Ophthalmic) Solution. Motion	PDL Status Under Review Seconded	Motion - Recommendations NPPA YES (√) √	Additional	Comments
1 Collins, Douglas, M.D. 2 May, J. Russell (Rusty) New Drug Ophthalmic Immunomodulators Board Members - Present (Strike out, when absent) 1 Avery, Mia, Pharm.D. 2 Doad, Gurinder J.S., M.D	Xiidra (Ophthalmic) Solution. Motion	PDL Status Under Review Seconded By (v)	Motion - Recommendations NPPA YES (√) √ √	Additional	Comments
1 Collins, Douglas, M.D. 2 May, J. Russell (Rusty) New Drug Ophthalmic Immunomodulators Board Members - Present (Strike out, when absent) 1 Avery, Mia, Pharm.D. 2 Doad, Gurinder J.S., M.D 3 Duraski, Rod, M.D.	Xiidra (Ophthalmic) Solution. Motion	PDL Status Under Review Seconded By (v)	Motion - Recommendations NPPA YES (√) √ √	Additional	Comments
1 Collins, Douglas, M.D. 2 May, J. Russell (Rusty) New Drug Ophthalmic Immunomodulators Board Members - Present (Strike out, when absent) 1 Avery, Mia, Pharm.D. 2 Doad, Gurinder J.S., M.D 3 Duraski, Rod, M.D. 4 Fincher, Deborah W., M.S., R.Ph Chair	Xiidra (Ophthalmic) Solution. Motion	PDL Status Under Review Seconded By (v)	Motion - Recommendations NPPA YES (V) √ √ √ √	Additional	Comments

Drug Utilization Review Board

Motions - Votes - New Drugs

FEBRUARY 7, 2017

8 Harris, Mary, Ph.D.			\checkmark		
₉ Lesnick, Burton, M.D Vice	\checkmark		\checkmark		
10 Lorys, Robyn Pharm.D.			\checkmark		
11 Miller, Osgood (Drew) A. R.Ph.			\checkmark		
12 Rollins, Brent L., R.Ph., Ph.D.			\checkmark		
13 Toth, Danny, R.Ph.			\checkmark		
		TOTAL	12	0	0
Board Members - Absent					
1 Collins, Douglas, M.D.					
2 May, J. Russell (Rusty)					
New Drug	Drug	PDL Status	Motion - Recommendations	Additiona	I Comments
Gout Agents			NDDA		
Board Members - Present	Zurampic (Oral) Tablet Motion	Under Review Seconded	NPPA	VOTES	
(Strike out, when absent)	Maker (V)	By (V)	YES (V)	NO (V)	ABSTAIN (√)
1 Avery, Mia, Pharm.D.			\checkmark		
2 Doad, Gurinder J.S., M.D			\checkmark		
3 Duraski, Rod, M.D.			\checkmark		
4 Fincher, Deborah W., M.S., R.Ph Chair					
5 Fowler, M. Celeste, Pharm.D.			\checkmark		
6 Gordon, Glenda Wrenn			\checkmark		
7 Graham, Yolanda, M.D.			\checkmark		
8 Harris, Mary, Ph.D.			\checkmark		
₉ Lesnick, Burton, M.D Vice			\checkmark		
10 Lorys, Robyn Pharm.D.	√		\checkmark		
11 Miller, Osgood (Drew) A. R.Ph.			\checkmark		
12 Rollins, Brent L., R.Ph., Ph.D.		\checkmark	\checkmark		

Drug Utilization Review Board Motions - Votes - New Drugs FEBRUARY 7, 2017

	TOTAL	12	0	0
Board Members - Absent				
1 Collins, Douglas, M.D.				
2 May, J. Russell (Rusty)				

Drug Utilization Review Board Meeting					
Febr	ruary 7, 2017				
Therapeutic Class	Drug Name	Current PDL/PIDL Status	DCH Decisions		
Dru	ıg Reviews				
Duchenne Muscular Dystophy					
	Exondys 51 (Intravenous) Injection (PIDL-only)	Non-PIDL	Still Under Review		
von Willebrand Factor Products					
	Vonvendi (Intravenous) Injection	NP/PA	NP/PA		
Ophthalmic Immunomodulators					
	Xiidra (Ophthalmic) Solution	Non-PDL	NP/PA		
Gout Agents					
PDL=Preferred Drug List; PIDL= Physician Injectable Druc	Zurampic (Oral) Tablet	Non-PDL	NP/PA		

.





Manufacturers' Forum ANNOUNCEMENT

NorthStar HealthCare Consulting Georgia Department of Community Health

On behalf of the Georgia Department of Community Health (DCH) and in service to the Georgia Medicaid Fee-for-Service (FFS) Drug Utilization Review Board (DURB), NorthStar HealthCare Consulting (NHC), in conjunction with OptumRx, announces the Manufacturers' Forum occurring Thursday, June 29, 2017, with an overflow day on Friday, June 30, 2017 only if needed.

Date: Thursday, June 29, 2017 from 9am-5pm EST Friday, June 30, 2017 from 9am-5pm EST (overflow day only if needed)

Location: NorthStar HealthCare Consulting 1121 Alderman Drive, Suite 112 Alpharetta, GA 30005

Appointments: The Manufacturers' Forum is by appointment only. Appointments may be requested and will be scheduled after the Drugs Under Review are posted to the DCH website at http://dch.georgia.gov/2017-durb-meeting-information approximately 30 days prior to the Forum. Manufacturers with drugs up for review at the current DURB meeting will be granted preference when seeking appointments. All requests for appointments must be made in writing to GAMedicaid@nhc-llc.com and include the drug name. New drug entities are generally not reviewed by the DURB until the drug has been on the market for at least 6 months.

Guidelines for Participation:


- To ensure equitable treatment of all manufacturers, individual manufacturer participation shall be limited to one 30-60 minute time segment per Forum. The presentation shall be limited to approximately 20-40 minutes with 10-20 minutes for questions and answers.
- Manufacturer presentations may be audio-recorded for review after the Forum.
- · For new drugs, manufacturers are highly encouraged to present all clinical information pertinent and relevant to current NHC clinical presentations to the DURB, to DCH drug benefit plan design and to other drugs within the class.
- For existing drugs, manufacturers are highly encouraged to present new clinical information since the drug was last reviewed by the DURB, especially clinical information related to comparisons of other drugs within the class.
- An electronic **one-page** summary (front only, font 10, not including references) of each drug presentation, factually based, in a stand-alone, user-friendly document should be provided one week prior to the presentation via email to GAMedicaid@nhc-llc.com. Please include a pronunciation guide of the drug's brand and generic names. The one-page summary will be provided to the DURB members.

Comments and Inquiries:

- Manufacturers with comments or inquiries related to Georgia Medicaid FFS Preferred Drug List, Prior Authorization Criteria, Manufacturers' Forum or DURB should submit these in writing to GAMedicaid@nhc-llc.com.
- Manufacturers with comments or inquiries related to Georgia Medicaid FFS supplemental rebates should submit these in writing to pba_gaoffers@changehealthcare.com.
- Manufacturers with comments or inquiries related to Georgia Medicaid FFS claims processing or drug benefit plan design should submit these in writing to Tami.Sweat@optum.com.

Georgia Department of Community Health (GDCH) Opportunities for Pharmaceutical Manufacturer Input on Clinical Recommendations and Clinical Management Strategies by the Drug Utilization Review Board

Clinical Information and Clinical Management Strategies relevant to the GDCH Medicaid Fee-For-Service program will be presented to the Drug Utilization Review Board (DURB) at each meeting through OptumRx by its vendor NorthStar HealthCare Consulting (NHC). Manufacturer input on new and existing drugs is welcomed and appreciated using these opportunities. **Please note that new drug entities are generally not reviewed by the DURB until the drug has been on the market for at least 6 months.**



Opportunity to Appeal to GDCH:

GDCH Review Process: DURB recommendations are reviewed by GDCH for final decisions. Manufacturers may request an appeal meeting directly with GDCH after conclusion of each quarterly DURB meeting and **this appeal meeting must be conducted within 10 business days following the DURB meeting**. <u>Contact: Shirmary Hodges at (404) 656-4044 or shodges@dch.ga.gov</u>

Questions not addressed in this document may be sent to NorthStar HealthCare Consulting by e-mail: <u>GAMedicaid@nhc-llc.com</u>

2017

Upcoming Meetings

Drug Utilization Review Board Meeting

2 Peachtree Street, N.W. 5th Floor Board Room Atlanta, Georgia 30303

Thursday, August 3, 2017:

9:30am – 1:30pm

Tuesday, November 7, 2017:

9:30am – 1:30pm

Manufacturers' Forum

NorthStar HealthCare Consulting

1121 Alderman Drive

Suite 112

Alpharetta, Georgia 30005

Thursday, June 29, 2017:

9:00am - 5:00pm

Tuesday, October 3, 2017:

9:00am - 5:00pm

Board Member	Credentials	Specialty/Area of Expertise	Company Name
Deborah W. Fincher, Chair	R.Ph., M.S.	HIV/AIDS Pharmacy	Pride Medical Pharmacy
Burton L. Lesnick, Vice-Chair	M.D., FAAP	Pediatrics/Pediatric Pulmonology	Children's Healthcare of Atlanta
Mia Avery	Pharm.D.	Oncology Pharmacy	Emory University Hospital Winship Cancer Institute
Douglas C. Collins	M.D.	Hematology/Oncology	Metro Hematology-Oncology, PC
Gurinder J.S. Doad	M.D., Ph.D.	Family Practice	Southwest Georgia Family Medicine and Mercer University School of Medicine
Rod M. Duraski	M.D., FACP, MBA	Internal Medicine	West Georgia Health
M. Celeste Fowler	Pharm.D., HCMBA	Hospital Pharmacy	Piedmont Henry Hospital
Glenda Gordon	M.D.	Psychiatry, Academia - Professor	Morehouse School of Medicine
Yolanda P. Graham	M.D.	Child and Adolescent Psychiatry	Devereux Georgia Treatment Network
Mary S. Harris	Ph.D.	Health Care Information/Education Research	BioTechnical Communications, Inc
Robyn Lorys	Pharm.D.	Academia - Professor	Mercer University College of Pharmacy
J. Russell May	Pharm.D.	Academia - Professor	University of Georgia College of Pharmacy
Drew A. Miller	R.Ph.	Retail Pharmacy	Wynn's Pharmacy
Brent L. Rollins	R.Ph., Ph.D.	Academia - Professor	Philadelphia College of Osteopathic Medicine School of Pharmacy
Danny A. Toth	R.Ph.	Pharmacy Benefit Plans	Timber Ridge Consultants, LLC